webinar series
The Lpa Challenge in Primary Prevention Who to Screen, Why It Matters, and What to do Next
What You'll Learn: Lp(a) Screening & Refined ASCVD Risk Assessment
This essential 1-hour session offers healthcare professionals critical insights and practical tools for elevating their understanding and application of Lipoprotein(a) [Lp(a)] screening in primary cardiovascular prevention.
Our esteemed expert panel will dissect the complexities of Lp(a), providing a detailed look at:
The fundamental structural characteristics and genetic determinants of Lp(a).
Its established role as a powerful, independent risk factor for Atherosclerotic Cardiovascular Disease (ASCVD).
The meeting provides actionable, practical guidance on:
Applying Lp(a) measurement to accurately refine ASCVD risk assessment.
Addressing logistical challenges, including discussions on optimal testing frequency and overcoming barriers to widespread testing.
Effective management strategies for patients with elevated Lp(a) levels.
The panel shares valuable clinical experiences and explores various existing treatment options, including an exciting look into the potential of emerging Lp(a)-lowering therapies. Conclude the session equipped with the knowledge to integrate effective Lp(a) screening and management into your own practice, leading to improved patient outcomes.
Learning Objectives
Describe the unique structure of Lipoprotein(a) [Lp(a)] and explain its causal role in atherothrombosis, distinguishing its risk pathway from that of LDL-C.
Identify the specific high-risk patient populations recommended for Lp(a) screening in a primary prevention setting, according to current international guidelines.
Apply Lp(a) measurement as a "risk-enhancing" factor to refine 10-year ASCVD risk assessment and guide the intensity of preventive therapies.
Evaluate the limited efficacy of current therapies (lifestyle, statins, PCSK9i) in managing elevated Lp(a) and summarize the evidence for aggressive management of all other modifiable risk factors.
Discuss the mechanism and trial status of emerging, targeted Lp(a)-lowering therapies (e.g., ASOs, siRNAs) and their potential future role.
The Faculty
Dr Franco WT Cheng – Moderator Moderating the session from Hong Kong, Dr. Cheng is a Pharmacist, Pharmacoepidemiologist, and Lecturer at The University of Hong Kong.
Dr Alberto J. Lorenzatti, MD, FFAC, FACC – Speaker Joining from Argentina, Dr. Lorenzatti is the Co-Director at DAMIC Medical Institute / Rusculleda Foundation for Research in Medicine, presenting on the Lp(a) challenge in primary prevention.
Dr Loh Wann Jia – Panelist Dr. Loh brings perspectives from Singapore, where she is a Senior Consultant Endocrinologist at Changi General Hospital and a Clinical Assistant Professor Duke-NUS.
Dr Dave L. Dixon – Panelist Joining from the USA, Dr. Dixon is a Professor and Chair in the Department of Pharmacotherapy & Outcomes Science at VCU School of Pharmacy.
Performed by:
restricted content
ISCP Members Only
Access to the e-Learning and Experts sections is available to ISCP Members only. Already a Member? Log in Not yet a Member? Visit our Registration page for details of how to join the ISCP and learn more about the benefits of being a part.